Towards continuous flow manufacturing of active pharmaceutical ingredients in Africa: a perspective

被引:0
|
作者
Nqeketo, Sinazo [1 ]
Sagandira, Cloudius R. [1 ]
机构
[1] Council Sci & Ind Res CSIR, Pharmaceut Technol, Pretoria, South Africa
来源
REACTION CHEMISTRY & ENGINEERING | 2024年 / 9卷 / 10期
基金
新加坡国家研究基金会;
关键词
DOLUTEGRAVIR; INHIBITORS; STAVUDINE; CHEMISTRY; HISTORY; BATCH; HIV; D4T;
D O I
10.1039/d4re00299g
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Africa has a double burden of communicable and non-communicable diseases, accounting for 26% of the global disease burden. Pharmaceutical medicines are critical components in treating these diseases; however, only 3% of global drug production is carried out in Africa, which results in limited access to medicines. The local active pharmaceutical ingredient (API) manufacturing industry is not well established. Africa hugely depends on imports. Thus, the need to establish local API manufacturing capability is obvious. In this review, we highlight the efforts and hurdles in the local manufacturing of APIs and recommend sustainable ways to establish local continuous flow API manufacturing capability. Continuous flow manufacturing is an innovative and enabling technology platform that is increasingly impacting the pharmaceutical industry. Africa can leverage continuous flow technology to establish a state-of-the-art, sustainable, competitive local API manufacturing industry. Although this approach is noble, it is not without its challenges. Some of the current challenges for the full-scale implementation of continuous flow manufacturing in Africa include the lack of pilot scale or demonstration facilities to bridge the chasm between research and commercialization, inadequate funding, prohibitive infrastructure costs and scarcity of skilled local talents with knowledge and expertise in modern manufacturing techniques. This review also showcases all examples in which continuous flow technology has been successfully applied exclusively in API syntheses within the African continent. The grand vision is to contribute towards the transformation of Africa into an innovation-led, technology-based and knowledge-based continent through the adoption of cutting edge innovative and enabling technologies. This can transform the local pharmaceutical industry into a responsive industry that meets continental health security, social, economic and political needs according to the African Union's Agenda 2063, Sustainable Development Goal 3 (SDG3) and Universal Health Coverage (UHC) goals. Building start-of-the-art, sustainable and competitive local API manufacturing in Africa using continuous flow technology.
引用
收藏
页码:2532 / 2551
页数:20
相关论文
共 50 条
  • [41] Practical methods for improving flow properties of active pharmaceutical ingredients
    Pingali, Kalyana C.
    Saranteas, Kostas
    Foroughi, Reza
    Muzzio, Fernando J.
    [J]. DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 2009, 35 (12) : 1460 - 1469
  • [42] A Perspective on Continuous Flow Chemistry in the Pharmaceutical Industry
    Baumann, Marcus
    Moody, Thomas S.
    Smyth, Megan
    Wharry, Scott
    [J]. ORGANIC PROCESS RESEARCH & DEVELOPMENT, 2020, 24 (10) : 1802 - 1813
  • [43] Polymorphism of active pharmaceutical ingredients
    Karpinski, PH
    [J]. CHEMICAL ENGINEERING & TECHNOLOGY, 2006, 29 (02) : 233 - 237
  • [44] Current good manufacturing practice design trends in active pharmaceutical ingredients facilities
    Angelucci, LA
    [J]. DRUG INFORMATION JOURNAL, 1999, 33 (03): : 739 - 746
  • [45] Theoretical approaches to physical transformations of active pharmaceutical ingredients during manufacturing processes
    Morris, KR
    Griesser, UJ
    Eckhardt, CJ
    Stowell, JG
    [J]. ADVANCED DRUG DELIVERY REVIEWS, 2001, 48 (01) : 91 - 114
  • [46] Synthetic challenges in the development of commercial manufacturing processes for two active pharmaceutical ingredients
    Savage, Scott
    Domagalski, Nathan
    Hobson, Lindsay
    Jones, Scott
    Mack, Brendan
    Qiu, Yuping
    Ramirez, Antonio
    Waltermire, Robert
    [J]. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2016, 252
  • [47] Current Good Manufacturing Practice Design Trends in Active Pharmaceutical Ingredients Facilities
    Louis A. Angelucci
    [J]. Drug information journal : DIJ / Drug Information Association, 1999, 33 : 739 - 746
  • [48] A RISK-BASED APPROACH TO MANAGING ACTIVE PHARMACEUTICAL INGREDIENTS IN MANUFACTURING EFFLUENT
    Caldwell, Daniel J.
    Mertens, Birgit
    Kappler, Kelly
    Senac, Thomas
    Journel, Romain
    Wilson, Peter
    Meyerhoff, Roger D.
    Parke, Neil J.
    Mastrocco, Frank
    Mattson, Bengt
    Murray-Smith, Richard
    Dolan, David G.
    Straub, Juerg Oliver
    Wiedemann, Michael
    Hartmann, Andreas
    Finan, Douglas S.
    [J]. ENVIRONMENTAL TOXICOLOGY AND CHEMISTRY, 2016, 35 (04) : 813 - 822
  • [49] Prequalification of active pharmaceutical ingredients
    [J]. WHO EXPERT COMMITTEE ON SPECIFICATIONS FOR PHARMACEUTICAL PREPARATIONS, 2015, 992 : 37 - 37
  • [50] Prequalification of active pharmaceutical ingredients
    [J]. WHO EXPERT COMMITTEE ON SPECIFICATIONS FOR PHARMACEUTICAL PREPARATIONS, 2013, 981 : 29 - 29